Literature DB >> 29237097

Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Konstantinos Stavropoulos1, Konstantinos P Imprialos1, Michael Doumas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29237097      PMCID： PMC8031205          DOI： 10.1111/jch.13146

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  30 in total

Review 1.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

2.  Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Kazuomi Kario; Ningling Sun; Fu-Tien Chiang; Ouppatham Supasyndh; Sang Hong Baek; Akiko Inubushi-Molessa; Ying Zhang; Hiromi Gotou; Martin Lefkowitz; Jack Zhang
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 4.  Diurnal blood pressure variation, risk categories and antihypertensive treatment.

Authors:  Alejandro de la Sierra; Julián Segura; Manuel Gorostidi; José R Banegas; Juan J de la Cruz; Luis M Ruilope
Journal:  Hypertens Res       Date:  2010-07-08       Impact factor: 3.872

Review 5.  Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?

Authors:  Costas Tsioufis; Kyriakos Dimitriadis; Athanasios Kordalis; Michalis Doumas; Dimitris Konstantinidis; Theodoros Kalos; Felix Mahfoud; Vasilios Papademetriou; Dimitrios Tousoulis
Journal:  Curr Vasc Pharmacol       Date:  2017       Impact factor: 2.719

6.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

Review 7.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

8.  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-13       Impact factor: 3.738

9.  Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Authors:  Sadayoshi Ito; Minoru Satoh; Yuko Tamaki; Hiromi Gotou; Alan Charney; Naoko Okino; Mizuki Akahori; Jack Zhang
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

Review 10.  The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.

Authors:  Pardeep S Jhund; John J V McMurray
Journal:  Heart       Date:  2016-05-20       Impact factor: 5.994
View more
  1 in total

1.  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-13       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.